Large Vessel Vasculitis: Symptoms, Causes, and Treatment

Large vessel vasculitis (LVV) is a group of inflammatory diseases that attack the walls of the body’s largest arteries, primarily the aorta and its major branches. The two conditions under this umbrella are giant cell arteritis (GCA) and Takayasu arteritis, and while they share striking similarities at the tissue level, they tend to strike different age groups and affect different parts of the arterial tree. GCA is far more common and typically appears in people over 50, while Takayasu arteritis usually begins before age 40. The symptoms range from persistent headaches and scalp tenderness to weak or absent pulses in the arms, and the stakes are high: untreated disease can lead to blindness, stroke, or life-threatening aortic damage.

Two Diseases or One Spectrum

The relationship between GCA and Takayasu arteritis has puzzled researchers for decades. Both involve granulomatous inflammation of large arteries, meaning immune cells cluster into characteristic nodules within the vessel wall. Both can produce giant cells, the fused multi-nucleated immune cells that give GCA its name. And both share overlapping genetic risk factors. These similarities have led some investigators to propose that GCA and Takayasu arteritis are actually variable presentations of the same underlying disease process rather than two separate conditions.¹

Still, their differences are clinically meaningful. A large international study that clustered over a thousand patients into distinct groups found that people with Takayasu arteritis were more likely to have disease in the abdominal vessels, both sides of the carotid and subclavian arteries, or isolated left subclavian disease. GCA patients, by contrast, more often showed diffuse arterial involvement, bilateral disease in the axillary and subclavian arteries, or minimal disease without a clear pattern. Takayasu arteritis also tended to produce visible structural damage on imaging, whereas GCA more often showed active inflammation on PET scans without the same degree of permanent vascular injury.²

Who Gets Large Vessel Vasculitis

GCA is the more common of the two by a wide margin. A population-based study in northern Italy found a standardized annual incidence of about 8 per 100,000 people aged 50 and older for GCA, compared with roughly 0.5 per million for Takayasu arteritis.³ GCA strongly favors women and people of Northern European descent, while Takayasu arteritis is more prevalent in East Asian, South Asian, and Middle Eastern populations. The age split is one of the sharpest distinctions: GCA almost never appears before 50, while Takayasu arteritis typically begins in the teens, twenties, or thirties.

Within GCA itself, there are subtypes worth knowing about. Some patients present with “cranial” GCA, dominated by headache, scalp tenderness, and jaw or visual symptoms. Others have “large-vessel” GCA, where inflammation primarily targets the aorta and its branches and can go undetected for longer because the classic head-related symptoms are absent. In the Italian cohort, cranial GCA was roughly twice as common as large-vessel GCA.³

Symptoms of Giant Cell Arteritis

The hallmark symptoms of GCA involve the head. New-onset headache is the most common complaint, often described as a persistent, throbbing pain concentrated around the temples. Jaw claudication, a cramping or aching pain in the jaw muscles when chewing, is another telltale sign and strongly predicts a positive diagnosis. Among GCA patients who developed visual problems, headache was present in about 62% and jaw claudication in about 55%.⁴ Scalp tenderness, particularly when touching or brushing the hair, is common. Some patients notice that the temporal artery itself feels thick, ropy, or tender to the touch.

About one in five GCA patients also has polymyalgia rheumatica (PMR), a condition causing stiffness and aching in the shoulders, neck, and hips, especially in the morning.⁴ PMR can appear before, during, or after the onset of GCA, and it sometimes exists on its own without progressing to full arteritis. Systemic symptoms like fatigue, fever, weight loss, and general malaise are also frequent and can dominate the picture early on, making the condition easy to mistake for an infection or cancer before the vascular symptoms declare themselves.

The most feared symptom is sudden vision loss. When inflamed temporal or ophthalmic arteries cut off blood supply to the eye, patients can lose vision in one eye within hours. If untreated, the second eye often follows. This is a medical emergency: every hour of delay in starting treatment worsens the chance of recovery.⁵

Symptoms of Takayasu Arteritis

Takayasu arteritis tends to unfold in two phases. The early phase is often called “prepulseless” because pulses are still intact and the symptoms are frustratingly vague: low-grade fever, malaise, night sweats, weight loss, joint pain, and fatigue.⁶ Many patients spend months or years being evaluated for other conditions before the diagnosis becomes clear. Blood work during this phase typically shows elevated inflammatory markers but offers few specific clues.

As inflammation narrows or blocks major arteries, the disease enters the “pulseless” phase. Clinically, this manifests as weak or absent pulses in one or both arms, differing blood pressure readings between arms, and symptoms of reduced blood flow: arm fatigue or cramping with use, dizziness, fainting, chest pain, or visual disturbances.⁶ If the renal arteries are involved, high blood pressure that is difficult to control can develop, sometimes as the presenting complaint in a young adult. Stenosis is the most common type of vascular lesion, and it is frequently bilateral. Among the most serious complications are Takayasu retinopathy, aortic valve regurgitation, and aneurysm formation.⁷

What Causes the Inflammation

The short answer is that the immune system mistakenly attacks the walls of large arteries, but the longer answer involves a cascade of failures in immune regulation. In GCA, the process appears to begin with inappropriate activation of certain innate immune cells, which triggers the body’s acute-phase inflammatory response and can produce the muscle pain and stiffness of polymyalgia rheumatica even before the arteries themselves are visibly inflamed. The adaptive immune system then loses its normal tolerance: a signaling pathway called NOTCH becomes dysregulated, leading to expansion of certain aggressive T cells while the regulatory T cells that would normally keep them in check become less effective.⁸

A critical step is the breakdown of the blood vessel’s internal barrier. Small blood vessels called vasa vasorum, which supply the walls of large arteries, develop a defective lining that allows immune cells to invade the arterial wall itself. Once inside, those cells encounter a permissive environment where an important immune brake, the PD-1/PD-L1 checkpoint, is not functioning properly. Without that brake, multiple types of inflammatory T cells thrive, shift toward energy-hungry metabolic states, and drive the formation of tissue-damaging macrophages, including the multinucleated giant cells the disease is named for.⁸

Genetics play a role as well. Both GCA and Takayasu arteritis are linked to specific regions of the human leukocyte antigen (HLA) system, which governs how the immune system distinguishes self from non-self. A large genetic analysis found that GCA susceptibility is most strongly tied to HLA class II genes, with variants near HLA-DRB1 showing the strongest signal. Takayasu arteritis, by contrast, is most strongly associated with HLA class I genes, particularly variants near HLA-B.⁹ A separate large-scale analysis confirmed that HLA class II molecules, especially specific amino acid positions in the DRβ1 and DQα1 proteins, are major contributors to GCA risk, consistent with the long-recognized association with the HLA-DRB1*04 allele.¹⁰ The different HLA associations between the two diseases may partly explain why they favor different ethnic populations.

How Large Vessel Vasculitis Is Diagnosed

Diagnosis can be one of the most frustrating parts of the journey. Blood tests showing elevated inflammatory markers like ESR and CRP are typically the first clue, but these markers are not specific to vasculitis and can be elevated in dozens of other conditions. Imaging and biopsy are needed to confirm the diagnosis.

For GCA, temporal artery biopsy has long been considered the gold standard. When positive, it is essentially conclusive, with a specificity of 100%. The sensitivity, however, sits around 77%, and false-negative rates range widely, from about 9% to 61% depending on the study.¹¹ False negatives happen because GCA can produce “skip lesions,” patchy areas of inflammation with normal artery in between, so a biopsy might sample an uninflamed segment. To reduce this risk, experts recommend performing the biopsy within one week of starting steroid treatment and obtaining a specimen at least 20 to 30 millimeters long.¹¹ In practice, one retrospective study found that only about 24% of biopsies come back positive, and the presence of jaw claudication was strongly associated with a positive result.¹²

Ultrasound of the temporal arteries has become an increasingly popular alternative to biopsy. The characteristic finding is a dark ring around the artery called the “halo sign,” caused by thickened, inflamed vessel walls. A meta-analysis of 23 studies found the halo sign had a pooled sensitivity of 67% and specificity of 95% for GCA diagnosis.¹³ When the halo sign appears on both sides, specificity approaches 100%, making bilateral ultrasound a strong non-invasive confirmatory tool.¹⁴ However, Cochrane review data show wide variability in ultrasound sensitivity across studies, with a median of 0.78 but a range stretching as low as 0.03 in some centers, reflecting how much the test depends on operator skill and equipment quality.¹⁵

For disease involving the aorta and its branches, whether in GCA or Takayasu arteritis, PET/CT scanning has become an important tool. It can detect active inflammation before structural damage has occurred, which allows earlier treatment. Preliminary data also suggest PET/CT can track how well treatment is working over time.¹⁶ Combined PET/MRI can go a step further by distinguishing an “inflammatory” pattern (active PET uptake plus abnormal MRI showing thickening or narrowing) from a “fibrous” pattern (abnormal MRI but no PET activity), helping clinicians tell active disease from old scarring.¹⁷

Treatment With Steroids

High-dose glucocorticoids remain the first-line treatment for both GCA and Takayasu arteritis and have been since the mid-twentieth century. For GCA, typical starting doses range from 40 to 60 milligrams of prednisolone daily, while PMR without arteritis usually calls for lower doses. There are no absolute guidelines on dose or duration; the regimen has to be tailored to each patient’s response, with gradual tapering over many months.¹⁸ When visual symptoms are present, steroid treatment is treated as a genuine emergency, and what matters most is how quickly the first dose is delivered, not whether it comes by IV or by mouth.⁵

The problem with steroids is that they work well but come at a cost. A French cohort study found that GCA patients received glucocorticoids for a median of 25 months, with roughly 64% experiencing at least one significant side effect. The most common complications were bone fractures and infections, each occurring in about 13% of patients, along with new-onset high blood pressure in 9%. Being over 75, having diabetes, or needing treatment for more than two years all increased the risk of side effects. Flares occurred in about 41% of patients while still on steroids, and about 22% who managed to stop steroids eventually relapsed.¹⁹ These numbers underscore why researchers have been looking for alternatives that can reduce steroid exposure.

Biologic and Steroid-Sparing Therapies

The most significant advance in GCA treatment in recent years has been tocilizumab, a biologic drug that blocks the interleukin-6 receptor. IL-6 is a key driver of the inflammatory cascade in GCA, and blocking it interrupts the disease at a critical point. A landmark randomized trial published in the New England Journal of Medicine found that about 56% of patients receiving weekly tocilizumab achieved sustained remission at one year, compared with only 14 to 18% of those on steroids alone. Tocilizumab also cut the cumulative steroid dose nearly in half.²⁰

Real-world data have supported these findings. A comparison of tocilizumab versus methotrexate (a conventional immunosuppressant sometimes used as a steroid-sparing agent) in two reference centers found that by 12 months, roughly 65% of tocilizumab-treated patients were in steroid-free remission, compared with only about 11% of those on methotrexate. Relapse rates at two years were numerically lower with tocilizumab but not statistically different between the groups.²¹ Tocilizumab is now widely considered the standard add-on therapy for GCA patients at high risk of steroid side effects or who relapse during tapering.

Surgical and Endovascular Interventions

When large vessel vasculitis causes severe narrowing or aneurysms, medications alone may not be enough. This is especially relevant in Takayasu arteritis, where progressive stenosis can threaten blood flow to vital organs. A multicenter retrospective study followed 79 Takayasu arteritis patients who underwent 166 vascular procedures, roughly two-thirds surgical bypasses and one-third endovascular repairs such as stenting. After a median follow-up of about six and a half years, complications had occurred after about 38% of surgical procedures and 50% of endovascular ones, with restenosis being the most frequent problem. One finding stood out: active inflammation at the time of the procedure dramatically increased the odds of complications, with an odds ratio of about 7.5. Patients who had complications had significantly higher inflammatory markers than those who did not.²² The clinical takeaway is that vascular procedures should ideally be performed during periods of disease quiescence whenever possible, because operating on actively inflamed vessels carries much higher failure rates.

Long-Term Vascular Complications

Even after the acute inflammation is controlled, large vessel vasculitis leaves a lasting mark on the arterial system. A population-based study found that GCA patients were over 17 times more likely to develop a thoracic aortic aneurysm than the general population of the same age and sex, and about 2.4 times more likely to develop an abdominal aortic aneurysm. Of the 11 patients in that cohort who developed thoracic aneurysms, six died suddenly of aortic dissection. The aneurysms typically appeared years after the initial diagnosis, with a median delay of nearly six years.²³ A separate multicenter study confirmed that patients with a history of large vessel vasculitis are prone to early aortic dissection and require ongoing monitoring of aortic size.²⁴ This means that even when a patient feels well and inflammatory markers have normalized, periodic imaging of the aorta remains important for years after diagnosis.

The Monitoring Problem

Tracking disease activity over time is harder than you might expect. The standard blood markers, ESR and CRP, are widely used but have significant limitations. They can remain normal during a genuine disease flare, and they are directly suppressed by tocilizumab, since the drug blocks the very IL-6 signaling that drives CRP production. A patient on tocilizumab could have actively inflamed arteries with perfectly normal blood work.²⁵ Despite extensive research, no reliable alternative blood biomarker has emerged. This gap means clinicians increasingly rely on vascular imaging, particularly ultrasound and PET, to supplement clinical assessment, especially when lab results are unreliable or the clinical picture is unclear.²⁶

Living With Large Vessel Vasculitis

The disease burden extends well beyond what shows up on imaging or blood tests. Patients with GCA report substantially worse fatigue and physical functioning compared to people of the same age in the general population, and this holds true even when the disease is technically in remission.²⁷ Active disease amplifies these effects, but even remission does not restore patients to baseline.

Qualitative research exploring patients’ own experiences has documented a range of impacts beyond the physical. Many patients describe persistent brain fog and difficulty concentrating. Irritability, low mood, and even depression are common, sometimes driven by the disease itself and sometimes by the effects of high-dose steroids, which can disrupt sleep, alter mood, and change personality. Some patients report anger at how long it took to get a correct diagnosis, a frustration that is especially common in Takayasu arteritis given its vague early symptoms. The emotional toll of depending on steroids while fearing their side effects creates its own psychological burden.²⁸

Pregnancy and Takayasu Arteritis

Because Takayasu arteritis predominantly affects women of reproductive age, pregnancy management is a real clinical concern. The disease can complicate pregnancy through hypertension, preeclampsia, and compromised blood flow to the placenta. A comprehensive analysis of maternal and fetal outcomes found that neither pre-pregnancy nor gestational use of glucocorticoids or immunosuppressants significantly reduced these complications, and antihypertensive therapy did not appear to correlate with lower preeclampsia rates either.²⁹ This does not mean treatment is useless during pregnancy, but it does mean that Takayasu arteritis pregnancies remain high-risk regardless of medical management, and close monitoring by both a rheumatologist and a maternal-fetal medicine specialist throughout is standard practice. Blood pressure monitoring is especially important because standard arm readings may be unreliable if the subclavian arteries are narrowed; clinicians sometimes need to measure pressure in the legs or use alternative methods to get accurate readings.

1
PubMed Central. Giant cell arteritis versus Takayasu’s Arteritis: Two sides of the same coin?
2
PubMed Central. Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis
3
PubMed. Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study
4
PubMed Central. Visual Manifestations in Giant Cell Arteritis: Trend over Five Decades in a Population-based Cohort
5
PubMed Central. Ocular Complications of Giant Cell Arteritis: An Acute Therapeutic Emergency
6
PubMed. Takayasu Arteritis: JACC Focus Seminar 3/4
7
PubMed Central. The Epidemiology and Clinical Manifestations of Takayasu Arteritis: A Descriptive Study of Case Reports
8
PubMed Central. Immunology of Giant Cell Arteritis
9
Scientific Reports. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy
10
PubMed Central. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility
11
PubMed Central. Temporal artery biopsy for suspected giant cell arteritis: A mini review
12
PubMed Central. Optimizing the use of temporal artery biopsy: a retrospective study
13
Rheumatology Advances in Practice. Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis
14
PubMed Central. Halo Sign on Temporal Artery Ultrasound Aids in Prompt Diagnosis of Giant Cell Arteritis
15
Cochrane Database of Systematic Reviews. Temporal artery ultrasound for diagnosing giant cell arteritis
16
PubMed. PET/CT for Diagnosis and Management of Large-Vessel Vasculitis
17
Scientific Reports. PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity
18
PubMed Central. Optimal management of giant cell arteritis and polymyalgia rheumatica
19
PubMed. A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects
20
PubMed. Trial of Tocilizumab in Giant-Cell Arteritis
21
PubMed Central. Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres
22
PubMed. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience
23
PubMed. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study
24
PubMed. Giant cell arteritis-related aortic dissection: A multicenter retrospective study
25
PubMed Central. Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides
26
Annals of the Rheumatic Diseases. New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritis
27
Arthritis & Rheumatology. Fatigue and Physical Functioning in Patients with Giant Cell Arteritis
28
Rheumatology. Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure
29
PubMed Central. Maternal-fetal outcomes and therapeutic strategies in pregnancies complicated by Takayasu arteritis: a comprehensive analysis